Extended cytogenetic follow-up of patients with myelodysplastic syndrome (MDS)

Publisher Website
Google Scholar
Abstract
The prognostic significance of clonal karyotype status in myelodysplastic syndrome (MDS) is assessed after an extended follow‐up period of 5 years. There are three prognostic sub‐groups according to the presence of a normal karyotype, single abnormalities or multiple abnormalities at the time of referral. However, there is no correlation between the size of the abnormal clone and prognosis. Karyotype status has independent prognostic significance in ‘high risk’MDS so that patients with a refractory anaemia with excess of blasts (RAEB)/RAEB in transformation (RAEB‐t) and a normal karyotype survive significantly longer than those with an abnormal karyotype (PPPP<0·05).